MobiNova Bio Completes Nearly RMB 100 Million Series A+ Financing to Lead the Single-Cell Sequencing Field

VCBeat (WeChat: vcbeat) has learned that recently, Mozhuo Biotechnology (Zhejiang) Co., Ltd. (hereinafter referred to as“MobiDrop”) announced the completion of its nearly RMB 100 million Series A+round of financing, led byLYFE Capital（LYFE Capital) as the lead investor, with existing shareholder Source Code Capital and the Yunxiang Fund, a local government guidance fund, participating in the follow-on investment, comprehensivelySupporting Corporate Development. It is reported that the funds raised in this round of financing will be primarily used to further expand the company's single-cell product R&D pipeline,Vigorously promote globalExclusiveofHigh-throughputMicrobial Single-Cell GenomicsLearning Platform (MobiMicrobe™）ofR&D andPromotion, and continuously advance the research, development, and production of various products,Commercialization and Market Expansion, focusing on accelerating collaboration with other industry practitionersBuild Diversity、EfficientSingle-cellEcosystem.

MobiDrop, founded at Harvard University in 2018, is dedicated to empowering scientific research and precision medicine with innovative microfluidics and single-cell sequencing technologies based on its world-leading droplet microfluidics platform. The company aims to upgrade the quality of diagnostics and testing, advance life science research, and provide more efficient solutions for researchers, physicians, and patients. Previously, in August 2021, MobiDrop secured RMB 150 million in Series A financing, led by Huagai Medical’s Yangtze River Delta Early-Stage Fund, with participation from Source Code Capital and Proxima Ventures. This latest Series A+ round has once again garnered favor from professional investors, underscoring MobiDrop’s robust independent innovation and R&D capabilities as well as its broad commercialization prospects.

Since its inception, MobiDrop has focused on the innovation and development of microfluidics and single-cell sequencing technologies. The company has established two major product lines—single-cell sequencing and digital PCR—and possesses core competencies in microfluidics, sequencing, biochemistry, hardware development, and bioinformatics. It is reported that MobiDrop is advancing multiple pipelines, including single-cell transcriptomics products, with more than 15 development projects currently underway.

MobiDrop's flagship product, MobiNova, currently available^®-100 High-Throughput Single-Cell Transcriptomics Solution, Including MobiNova^®-100 Single-Cell Sequencing Library Preparation System, MobiCube^®Single-Cell Transcriptome Library Preparation Reagents and Chips, and MobiVision^®Bioinformatics Analysis Software. This series of products rivals top international standards, enabling high-quality, cost-effective, and comprehensive replacement solutions. Its applications span multiple fields, including life sciences research, liquid biopsy, and companion diagnostics.

Furthermore, MobiDrop’s products have achieved technological breakthroughs in the global field of microbiology. Its MobiMicrobe™ high-throughput single-cell genomic sequencing technology for microbes has ushered microbial research into the era of high-throughput single-cell analysis. The related findings were published in the world-renowned journal Science, attracting widespread attention and demonstrating significant scientific importance and application value.

Dr. Hao Pei, Founder and CEO of MobiDropStatement: Leveraging its internationally leading technological expertise and years of accumulated strength, the MobiDrop team has efficiently developed MobiNova, a single-cell sequencing technology platform and product suite that ranks among the best in China.^®-100 high-throughput single-cell transcriptomics solution, officially embarking on its commercialization journey this year. The successful completion of this financing round represents the capital market and industry’s profound understanding and recognition of the single-cell sequencing sector and MobiDrop. We sincerely thank LYFE Capital and our existing investors for their trust and support in MobiDrop. Following this financing round, MobiDrop will allocate more resources to building a comprehensive single-cell multi-omics product matrix, continuously expanding its product line, enriching product dimensions, and establishing a robust product system and technological barriers. We will continue to increase throughput and reduce costs, making single-cell technology accessible to more scientific research, accelerating the translation of research into clinical applications, and serving life and health. MobiDrop is committed to creating an integrated R&D platform for both domestic and international markets, looking forward to working with other industry practitioners to build a diverse and efficient ecosystem.

Guo Zhenjun, Vice President of Investment at LYFE CapitalMobiDrop has cultivated deep expertise in microfluidics and single-cell sequencing technologies for many years, establishing solid, systematic technological and platform advantages. Currently, the application of single-cell analysis in scientific research is widely recognized, and its expansion into clinical applications holds immense potential. We are confident that MobiDrop’s mature management model, top-tier R&D capabilities, and robust commercialization strategy will lead the company to new heights. LYFE Capital has long focused on the biopharmaceutical sector; we remain firmly bullish on MobiDrop’s long-term development and will join forces with both existing and new shareholders to provide comprehensive support and assistance for the company’s growth.

Investor at Source Code CapitalIt was stated that MobiDrop’s pioneering high-throughput single-cell sequencing technology for microorganisms has achieved a scientific breakthrough in the field of microbiomics, representing a new paradigm of cross-disciplinary integration in the life sciences. The founding team of MobiDrop boasts diverse backgrounds and cross-disciplinary expertise, along with decades of R&D and commercialization experience at top-tier multinational medical device companies. Source Code Capital has consistently prioritized cross-disciplinary innovation and will leverage its extensive industry experience and global resource network to support MobiDrop’s continuous innovation. There is high expectation that MobiDrop will achieve even greater development by leveraging its scientific research achievements.

Wen Guangyu, Yunxiang FundIt stated: “As an innovation-driven scientific research and precision medicine enterprise, MobiDrop is committed to providing users with superior products and services to help them achieve their research and clinical objectives, thereby realizing its vision of serving human health through life sciences. Single-cell sequencing has been explicitly included in the National Key R&D Program for the biomedical industry under the 14th Five-Year Plan, fully reflecting the strategic significance of this technology. We look forward to collaborating with MobiDrop to jointly accelerate the clinical translation and application of single-cell multi-omics.”

LYFE Capital is a globally leading healthcare investment platform. We firmly believe that "healthcare knows no borders," and every investment decision we make is dedicated to advancing biomedical progress and addressing unmet clinical needs worldwide. Leveraging our extensive investment management expertise and global industry resources, LYFE Capital creates value for its portfolio companies. Our integrated international investment team provides comprehensive support to pioneering enterprises at all stages, helping entrepreneurs fully realize their growth potential in the global market.

Source Code Capital is a venture capital firm with an entrepreneurial spirit. Since its establishment in spring 2014, Source Code has remained committed to investing in technology-driven innovation and the creation of enduring, tangible value. It has invested in more than 300 startups (including ByteDance, Meituan (3690.HK), Ke Holdings (NYSE:BEKE), and Li Auto (NASDAQ:LI, 2015.HK)), spanning seed, early, and growth stages, across industries such as life sciences, green development, intelligent manufacturing, industrial digitalization, global expansion, and consumer technology. The total assets under management of Source Code’s RMB and USD funds are equivalent to approximately RMB 35 billion.

Yunxiang Fund was established in December 2019. It is a private equity investment firm focusing on intelligent manufacturing within strategic emerging industries. As a government-guided fund, it was set up by Wuzhen to better advance the “One Zone, Three Bases” initiative and support entrepreneurship, innovation, and industrial transformation and upgrading in Wuzhen. The fund primarily invests in projects that have been or are planned to be settled under the “Wuzhen Academician Intelligence Valley” platform.